TCI Wealth Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

TCI Wealth Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-660	Closed	-$4.88K	–	2649
2022 Q4	$4.88K	Buy	+660	New	+$6.43K	﹤0.01%	1537
2021 Q3	–	Sell	-137	Closed	-$3K	–	2584
2021 Q2	$3K	Buy	137 +31	+29%	+$555	﹤0.01%	1866
2021 Q1	$2K	Buy	+106	New	+$1.72K	﹤0.01%	1918
2019 Q1	–	Sell	-56	Closed	-$1K	–	1560
2018 Q4	$1K	Buy	+56	New	+$1.32K	﹤0.01%	1328

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCI Wealth Advisors's VNDA Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 660 shares — an estimated $4.88K sold.

TCI Wealth Advisors first reported a position in VNDA in Q4 2018 and held it in 4 quarters. The position peaked at $4.88K in Q4 2022. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

TCI Wealth Advisors reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
TCI Wealth Advisors sold 660 Vanda Pharmaceuticals shares in Q1 2023, an estimated $4.88K.
TCI Wealth Advisors first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 4 quarters.
TCI Wealth Advisors's Vanda Pharmaceuticals position peaked at $4.88K in Q4 2022.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.